Skip to main content
Canna~Fangled Abstracts

Medical Cannabis, Headaches, and Migraines: A Review of the Current Literature

By August 24, 2021September 30th, 2021No Comments
Review

doi: 10.7759/cureus.17407. eCollection 2021 Aug.

Affiliations 

Abstract

Cannabis has been long used since ancient times for both medical and recreational use. Past research has shown that cannabis can be indicated for symptom management disorders, including cancer, chronic pain, headaches, migraines, and psychological disorders (anxiety, depression, and post-traumatic stress disorder). Active ingredients in cannabis that modulate patients’ perceptions of their conditions include Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), flavonoids, and terpenes. These compounds work to produce effects within the endocannabinoid system to decrease nociception and decrease symptom frequency. Research within the United States of America is limited to date due to cannabis being classified as a schedule one drug per the Drug Enforcement Agency. Few anecdotal studies have found a limited relationship between cannabis use and migraine frequency. The purpose of the review article is to document the validity of how medical cannabis can be utilized as an alternative therapy for migraine management. Thirty-four relevant articles were selected after a thorough screening process using PubMed and Google Scholar databases. The following keywords were used: “Cannabis,” “Medical Marijuana,” “Headache,” “Cannabis and Migraine,” “Cannabis and Headache.” This literature study demonstrates that medical cannabis use decreases migraine duration and frequency and headaches of unknown origin. Patients suffering from migraines and related conditions may benefit from medical cannabis therapy due to its convenience and efficacy.

 

Keywords: cannabis, cannabis and headache, cannabis and migraine, headache, medical marijuana

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Medical reasons for marijuana use, forms of use, and patient perception of physician attitudes among the US population. Azcarate PM, Zhang AJ, Keyhani S, Steigerwald S, Ishida JH, Cohen BE. J Gen Intern Med. 2020;35:1979–1986. – PMC – PubMed
    1. Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science. Baron EP. https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.13345. Headache. 2018;58:1139–1186. – PubMed
    1. Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells. Giudice ED, Rinaldi L, Passarotto M, et al. https://jlb.onlinelibrary.wiley.com/doi/full/10.1189/jlb.1206738. J Leukoc Biol. 2007;81:1512–1522. – PubMed
    1. Cannabis and neuropsychiatric disorders: an updated review. Chayasirisobhon S. https://pubmed.ncbi.nlm.nih.gov/31867704/ Acta Neurol Taiwan. 2019;28(2):27–39. – PubMed
    1. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Russo EB. https://pubmed.ncbi.nlm.nih.gov/18404144/ Neuro Endocrinol Lett. 2008;29:192–200. – PubMed

Publication types


Leave a Reply